Dabrafenib, marketed under the brand name Tafinlar, is a prescription medication used to treat certain types of cancers. Specifically, dabrafenib is indicated for the treatment of melanoma with BRAF V600E or V600K mutations, as well as non-small cell lung cancer with BRAF V600E mutations. Dabrafenib belongs to a class of medications known as BRAF inhibitors, which work by targeting a specific genetic mutation found in some cancer cells. The mechanism of action of dabrafenib is relatively straightforward. In normal cells, a protein called BRAF helps to regulate cell growth and division. However, in some cancer cells, the BRAF protein is mutated, causing it to become overactive and to promote uncontrolled cell growth. Dabrafenib works by specifically targeting and inhibiting the activity of the mutated BRAF protein, which in turn slows or stops the growth and division of cancer cells. Dabrafenib (Tafinlar) Capsules is a small molecule inhibitor that works by binding to the ATP-bin...
Comments
Post a Comment